Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Pharmacology & Therapeutics|November 21, 2002
Lithium and valproic acid: parallels and contrasts in diverse signaling contextsNadia Gurvich, Peter S KleinCancer Research|February 12, 2004
Histone deacetylase is a target of valproic acid-mediated cellular differentiationNadia Gurvich, Oxana M Tsygankova, Judy L Meinkoth, et al.The Journal of Biological Chemistry|June 11, 2003
Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3Fang Zhang, Christopher J Phiel, Laura Spece, et al.Proceedings of the National Academy of Sciences of the United States of America|December 15, 2010
L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stabilityNadia Gurvich, Fabiana Perna, Andrea Farina, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 20, 2005
Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivoNadia Gurvich, Melissa G Berman, Ben S Wittner, et al.Cancer Research|May 28, 2011
The mef/elf4 transcription factor fine tunes the DNA damage responseGoro Sashida, Narae Bae, Silvana Di Giandomenico, et al.Blood|June 30, 2010
Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia veraFabiana Perna, Nadia Gurvich, Ruben Hoya-Arias, et al.Biorxiv : the Preprint Server for Biology|December 11, 2023
Patient-Specific Vascularized Tumor Model: Blocking TAM Recruitment with Multispecific Antibodies Targeting CCR2 and CSF-1RHuu Tuan Nguyen, Nadia Gurvich, Mark Robert Gillrie, et al.Biomaterials|August 17, 2024
Patient-specific vascularized tumor model: Blocking monocyte recruitment with multispecific antibodies targeting CCR2 and CSF-1RHuu Tuan Nguyen, Ellen L Kan, Mouhita Humayun, et al.Pageof 1